How hospital expansions are reshaping India’s healthcare sector

Growth in the healthcare sector extends beyond physical infrastructure, with specialty care and diagnostics continuing to gain momentum.

Healthcare providers entered FY27 on a strong footing, with capacity expansion, specialty-led growth and network development continuing across hospitals and diagnostics. During the quarter, providers accelerated bed additions, expanded diagnostic infrastructure and reported sustained demand for high-acuity specialties, advanced procedures and premium diagnostic services. The sector also witnessed increased policy focus on healthcare affordability, accessibility and pricing transparency, with a series of recommendations aimed at improving patient access and reducing the cost of care.

How hospital capacity is expanding in India

Around 2,000 beds were added, commissioned or acquired across major listed healthcare providers during Q1FY27, reflecting continued capacity expansion across the healthcare sector. Most of the incremental capacity was added in metro and Tier-I markets, primarily through the expansion of existing facilities and established hospital clusters, while non-metro and Tier-II market expansion comprised new facilities and acquisition-led expansion. 

Looking ahead, major listed providers have announced an aggregate pipeline of approximately 20,000 beds over the next three to five years. While a significant portion of upcoming capacity is planned within existing markets, a number of announced projects are also directed towards non-metro and Tier-II locations, indicating continued expansion beyond established healthcare hubs. 

How expansion and high-acuity specialties are driving healthcare sector growth

Hospital chains reported strong growth during Q1FY27, with revenues increasing by approximately 22% y-o-y, supported by higher patient volumes of approximately 16% and improved realizations, reflected in ARPP/ARPOB growth of approximately 6%. Growth was driven by sustained demand for high-acuity specialties such as cardiology, oncology, neurosciences, gastroenterology and orthopedics, alongside increasing volumes of other advanced procedures. The resulting shift towards a richer clinical mix supported blended realization growth across hospital networks. While EBITDA margins remained healthy across the sector, some hospitals reported margin moderation due to ramp-up costs associated with newly commissioned facilities and the integration of acquired assets. 

Diagnostic companies reported strong growth during Q1FY27, with revenues increasing by approximately 18% y-o-y, supported by growth in test volumes of approximately 11% and improved realizations of approximately 6%. Volume growth, supported by network expansion, remained a key growth driver. Expansion activity is increasingly focused on broadening access and strengthening network penetration across non-metro and Tier-II and Tier-III markets. Companies also expanded their portfolios across specialty diagnostics, genomics and other advanced testing capabilities, supporting a richer test mix and contributing to higher realizations. 

Policy measures aimed at improving healthcare affordability

The parliamentary committee's recommendations focus on improving healthcare affordability and access through a combination of pricing reforms, transparency measures, insurance expansion and healthcare infrastructure development. Key proposals include standardization and rationalization of healthcare costs, elimination of room rent-linked pricing for procedures, and capping hospital room charges in line with prevailing three-star hotel tariffs in the vicinity. The recommendations propose the introduction of national ceiling prices for high-volume diagnostics such as PET-CT, MRI and genetic profiling, alongside broader price regulation for treatments, medical devices and consumables. Mandatory pre-admission price transparency, a dedicated healthcare ombudsman for billing and insurance disputes, and stronger patient protection measures are proposed to improve transparency. In addition, the recommendations call for expanding coverage of public healthcare schemes and overall government expenditure on healthcare to enhance healthcare accessibility across the country.

Healthcare deal activity remains resilient despite a muted PE/M&A quarter

While Q1FY27 did not see the consummation of major PE/M&A deals, transaction activity remains buoyant, with strong traction across the multi-specialty and medical devices segments. In addition, the IPO market remains active, with healthcare issuers continuing to tap public markets amid favorable sector fundamentals.